Search

Gyan Chandra

Examiner (ID: 12063, Phone: (571)272-2922 , Office: P/1646 )

Most Active Art Unit
1646
Art Unit(s)
1646, 1674
Total Applications
1424
Issued Applications
820
Pending Applications
137
Abandoned Applications
480

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18451522 [patent_doc_number] => 20230192800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/927150 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927150 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/927150
LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE May 23, 2021 Pending
Array ( [id] => 17256830 [patent_doc_number] => 20210369815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => GLUCOSE RESPONSIVE INSULINS [patent_app_type] => utility [patent_app_number] => 17/327498 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327498 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/327498
Glucose responsive insulins May 20, 2021 Issued
Array ( [id] => 19521116 [patent_doc_number] => 12122824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis [patent_app_type] => utility [patent_app_number] => 17/320490 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 61141 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 294 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320490 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/320490
Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis May 13, 2021 Issued
Array ( [id] => 20882283 [patent_doc_number] => 12698314 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Extended time action acylated insulin compounds [patent_app_type] => utility [patent_app_number] => 17/998090 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7252 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998090 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/998090
EXTENDED TIME ACTION ACYLATED INSULIN COMPOUNDS May 12, 2021 Pending
Array ( [id] => 18142268 [patent_doc_number] => 20230016112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => ENGINEERED CD25 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/320118 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/320118
Engineered CD25 polypeptides and uses thereof May 12, 2021 Issued
Array ( [id] => 19717359 [patent_doc_number] => 12202882 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/315168 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 60255 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315168 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/315168
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof May 6, 2021 Issued
Array ( [id] => 17505457 [patent_doc_number] => 20220098559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => ISOLATED GDF TRAP POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 17/243049 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243049 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/243049
ISOLATED GDF TRAP POLYPEPTIDE Apr 27, 2021 Abandoned
Array ( [id] => 17020929 [patent_doc_number] => 20210244800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => Use of Ultrarapid Acting Insulin [patent_app_type] => utility [patent_app_number] => 17/240802 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240802 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/240802
Use of ultrarapid acting insulin Apr 25, 2021 Issued
Array ( [id] => 19042345 [patent_doc_number] => 11931418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Methods of treating severe inflammation [patent_app_type] => utility [patent_app_number] => 17/240558 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 2 [patent_no_of_words] => 17419 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240558 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/240558
Methods of treating severe inflammation Apr 25, 2021 Issued
Array ( [id] => 19439980 [patent_doc_number] => 12090206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels [patent_app_type] => utility [patent_app_number] => 17/238632 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 11 [patent_no_of_words] => 10676 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 460 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238632 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/238632
Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels Apr 22, 2021 Issued
Array ( [id] => 19916213 [patent_doc_number] => 12291566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis [patent_app_type] => utility [patent_app_number] => 17/237650 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 51740 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 285 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237650 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/237650
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis Apr 21, 2021 Issued
Array ( [id] => 17256632 [patent_doc_number] => 20210369617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/224068 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224068 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/224068
Lyophilized mesenchymal stem cell derived secretome and uses thereof Apr 5, 2021 Issued
Array ( [id] => 18518535 [patent_doc_number] => 11708416 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Methods of treating severe insulin resistance by interfering with glucagon receptor signaling [patent_app_type] => utility [patent_app_number] => 17/222236 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 15678 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222236 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/222236
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling Apr 4, 2021 Issued
Array ( [id] => 18947048 [patent_doc_number] => 11890321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => Method of treating or inhibiting glucose intolerance [patent_app_type] => utility [patent_app_number] => 17/203640 [patent_app_country] => US [patent_app_date] => 2021-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203640 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/203640
Method of treating or inhibiting glucose intolerance Mar 15, 2021 Issued
Array ( [id] => 18836810 [patent_doc_number] => 11844867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device [patent_app_type] => utility [patent_app_number] => 17/202119 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 24214 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17202119 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/202119
Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device Mar 14, 2021 Issued
Array ( [id] => 18962934 [patent_doc_number] => 11896673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Glucose responsive insulin delivery compositions and methods [patent_app_type] => utility [patent_app_number] => 17/188583 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 57 [patent_no_of_words] => 10215 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188583 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/188583
Glucose responsive insulin delivery compositions and methods Feb 28, 2021 Issued
Array ( [id] => 17356843 [patent_doc_number] => 20220017639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS FOR INCREASING THERMOGENIC ADIPOCYTES [patent_app_type] => utility [patent_app_number] => 17/186072 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186072 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/186072
METHODS FOR INCREASING THERMOGENIC ADIPOCYTES Feb 25, 2021 Abandoned
Array ( [id] => 18057985 [patent_doc_number] => 20220389071 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-12-08 [patent_title] => LONG-LASTING GLP1 ANALOGUE DRUG FOR TYPE-2 DIABETES [patent_app_type] => utility [patent_app_number] => 17/184248 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184248 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/184248
Long-lasting GLP1 analogue drug for type-2 diabetes Feb 23, 2021 Issued
Array ( [id] => 18057985 [patent_doc_number] => 20220389071 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-12-08 [patent_title] => LONG-LASTING GLP1 ANALOGUE DRUG FOR TYPE-2 DIABETES [patent_app_type] => utility [patent_app_number] => 17/184248 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184248 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/184248
Long-lasting GLP1 analogue drug for type-2 diabetes Feb 23, 2021 Issued
Array ( [id] => 18339375 [patent_doc_number] => 20230131324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => FORMULATIONS OF ANTI-ENDOTHELIAL LIPASE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/801670 [patent_app_country] => US [patent_app_date] => 2021-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -90 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801670 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/801670
FORMULATIONS OF ANTI-ENDOTHELIAL LIPASE ANTIBODIES Feb 22, 2021 Pending
Menu